Alivus Q1 net profit up 32% YoY to ₹160 Cr as margins hit record ~33%

Alivus Life Sciences (formerly Glenmark Life Sciences) opened FY27 with a profit-led quarter: standalone net profit rose 31.7% YoY to ₹160.08 Cr on revenue of ₹640.41 Cr (+6.4% YoY), the gap between the two lines being the whole story — this was margin, not volume. EBITDA margin expanded to roughly 33% (from 28.6% a year ago) and net margin to 24.2% of total income (from 19.9%), driven by a favourable raw-material line (cost of materials at ₹253.1 Cr was actually below the ₹269.0 Cr of the year-ago quarter despite higher sales) and operating leverage on a lean cost base. There were no exceptional items this quarter, so the reported +31.7% PAT growth is also the clean underlying number.

Sequentially the print softened — revenue fell 7.1% and PAT eased 1.6% versus the seasonally strong Q4 (₹689.1 Cr / ₹162.7 Cr) — but Q4 is the company's peak quarter and the QoQ dip is a seasonality artifact rather than deterioration; YoY is the right lens and it is firmly positive. Against management's own framing, the quarter validates the margin thesis: the FY26 concall had upgraded EBITDA-margin guidance to 30-32% and reaffirmed high-single-digit revenue growth, and Q1 delivers ~33% margins (ahead of the guided band) with 6.4% topline growth (mid/high-single-digit, a touch below the ~10.7% FY27 revenue-growth pace the street is modelling).

The stock went into the print at ₹1,111, down 2.5% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Single API reporting segment — standalone-only (no consolidated statement); limited review, unmodified conclusion

Street consensus (3 analysts, per Trendlyne) sits around a ₹1,158 target with 10.7% FY27 revenue growth expected; the Q1 topline is modestly light of that trajectory while profitability runs ahead, leaving the print broadly in line with a positive skew on margins. Board actions this quarter were routine (trading-window closure, the July 30 results meeting). The key operational trigger flagged by management — the Solapur greenfield facility slated for Q2 FY27 — is what underpins the double-digit growth guidance from FY28; this quarter's job was to hold record margins while that capacity comes on, and it did.